BioCentury | Sep 16, 2019
Company News

Management tracks: Gottlieb joins FasterCures’ board; plus Foghorn, Varian

...VP and head of clinical development at Agios Pharmaceuticals Inc. (NASDAQ:AGIO). Reine was CFO at Pieris...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

...cell therapies. A February 2018 deal with Pieris Pharmaceuticals Inc. gave Seattle Genetics access to Pieris’...
...platform to develop bispecific candidates to treat solid tumors and blood cancers. The deal combines Pieris’...
...AG (Xetra:BAYN), Leverkusen, Germany bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. ISA Pharmaceuticals B.V., Leiden, Netherlands Pieris...
BioCentury | May 30, 2018
Company News

Management tracks: Zafgen, Rigel

...Development and Manufacturing Scott Lauder to chief technology officer. Knopf was SVP and CBO at Pieris...
BioCentury | Apr 26, 2018
Product R&D

Brake for gas

...bispecific compounds that target 4-1BB on T cells and a protein on tumor cell surfaces. Pieris...
...Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE: PFE), New York, N.Y. Pieris...
...plc Bristol-Myers Squibb Co. Elpiscience Biopharmaceuticals Co. Ltd. Enumeral Biomedical Holdings Inc. Harvard Medical School Inhibrx LLC Merck & Co. Inc. Pfizer Inc. Pieris...
BioCentury | Feb 23, 2018
Financial News

Pieris raises $50.6M in follow-on

...Anticalin company Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) raised $50.6 million through the sale of 6.3 million shares...
...$9.45 on Feb 13, before the offering was proposed. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. Shannon Lehnbeuter Pieris...
BioCentury | Feb 16, 2018
Company News

Seattle Genetics, Pieris partner for immuno-oncology

...Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) partnered to develop bispecific...
...bispecific candidates to treat solid tumors and blood cancers. The partners will develop candidates using Pieris'...
...Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. Business: Cancer Allison Johnson Pieris...
BioCentury | Feb 9, 2018
Product R&D

R is for readout

...includes mRNAs from Moderna Therapeutics Inc., cyclic peptides from Bicycle Therapeutics Ltd., and anticalins from Pieris...
...Pharmaceuticals Inc. (NASDAQ:IONS), Carlsbad, Calif. Methuselah Health Inc., Wilmington, Del. Moderna Therapeutics Inc., Cambridge, Mass. Pieris...
...Drug Discovery (2018) Karen Tkach Tuzman, Associate Editor AstraZeneca plc Bicycle Therapeutics Ltd. Ionis Pharmaceuticals Inc. Methuselah Health Inc. Moderna Therapeutics Inc. Pieris...
BioCentury | Feb 9, 2018
Company News

Seattle Genetics, Pieris in immuno-oncology deal

...Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) partnered to develop bispecific...
...bispecific candidates to treat solid tumors and blood cancers. The partners will develop candidates using Pieris'...
...Pieris jumped $1.44 (20%) to $8.59 on Friday. Seattle Genetics was off $0.40 to $50.14. Allison Johnson Pieris...
BioCentury | Nov 3, 2017
Clinical News

Pieris begins Phase I of PRS-343 in solid tumors

...anticalin targeting tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB; TNFRSF9; CD137) and HER2. Pieris...
...HER2-positive solid tumors Endpoint: Safety and anti-cancer activity Status: Phase I started Milestone: NA Elizabeth S. Eaton PRS-343 Pieris...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...He was president of global R&D at Pacira Pharmaceuticals Inc. (NASDAQ:PCRX). Cancer and hematology company Pieris...
Items per page:
1 - 10 of 110
BioCentury | Sep 16, 2019
Company News

Management tracks: Gottlieb joins FasterCures’ board; plus Foghorn, Varian

...VP and head of clinical development at Agios Pharmaceuticals Inc. (NASDAQ:AGIO). Reine was CFO at Pieris...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

...cell therapies. A February 2018 deal with Pieris Pharmaceuticals Inc. gave Seattle Genetics access to Pieris’...
...platform to develop bispecific candidates to treat solid tumors and blood cancers. The deal combines Pieris’...
...AG (Xetra:BAYN), Leverkusen, Germany bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. ISA Pharmaceuticals B.V., Leiden, Netherlands Pieris...
BioCentury | May 30, 2018
Company News

Management tracks: Zafgen, Rigel

...Development and Manufacturing Scott Lauder to chief technology officer. Knopf was SVP and CBO at Pieris...
BioCentury | Apr 26, 2018
Product R&D

Brake for gas

...bispecific compounds that target 4-1BB on T cells and a protein on tumor cell surfaces. Pieris...
...Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE: PFE), New York, N.Y. Pieris...
...plc Bristol-Myers Squibb Co. Elpiscience Biopharmaceuticals Co. Ltd. Enumeral Biomedical Holdings Inc. Harvard Medical School Inhibrx LLC Merck & Co. Inc. Pfizer Inc. Pieris...
BioCentury | Feb 23, 2018
Financial News

Pieris raises $50.6M in follow-on

...Anticalin company Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) raised $50.6 million through the sale of 6.3 million shares...
...$9.45 on Feb 13, before the offering was proposed. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. Shannon Lehnbeuter Pieris...
BioCentury | Feb 16, 2018
Company News

Seattle Genetics, Pieris partner for immuno-oncology

...Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) partnered to develop bispecific...
...bispecific candidates to treat solid tumors and blood cancers. The partners will develop candidates using Pieris'...
...Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. Business: Cancer Allison Johnson Pieris...
BioCentury | Feb 9, 2018
Product R&D

R is for readout

...includes mRNAs from Moderna Therapeutics Inc., cyclic peptides from Bicycle Therapeutics Ltd., and anticalins from Pieris...
...Pharmaceuticals Inc. (NASDAQ:IONS), Carlsbad, Calif. Methuselah Health Inc., Wilmington, Del. Moderna Therapeutics Inc., Cambridge, Mass. Pieris...
...Drug Discovery (2018) Karen Tkach Tuzman, Associate Editor AstraZeneca plc Bicycle Therapeutics Ltd. Ionis Pharmaceuticals Inc. Methuselah Health Inc. Moderna Therapeutics Inc. Pieris...
BioCentury | Feb 9, 2018
Company News

Seattle Genetics, Pieris in immuno-oncology deal

...Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) partnered to develop bispecific...
...bispecific candidates to treat solid tumors and blood cancers. The partners will develop candidates using Pieris'...
...Pieris jumped $1.44 (20%) to $8.59 on Friday. Seattle Genetics was off $0.40 to $50.14. Allison Johnson Pieris...
BioCentury | Nov 3, 2017
Clinical News

Pieris begins Phase I of PRS-343 in solid tumors

...anticalin targeting tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB; TNFRSF9; CD137) and HER2. Pieris...
...HER2-positive solid tumors Endpoint: Safety and anti-cancer activity Status: Phase I started Milestone: NA Elizabeth S. Eaton PRS-343 Pieris...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...He was president of global R&D at Pacira Pharmaceuticals Inc. (NASDAQ:PCRX). Cancer and hematology company Pieris...
Items per page:
1 - 10 of 110